Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Viking TherapeuticsClinical-stage biotech. VK2735: dual GLP-1/GIP in oral and injectable formulations; VENTURE-Oral Phase 2 hit 10.9% placebo-adjusted weight loss at 13 weeks. Most-discussed mid-cap obesity pure-play.
Q4 2022-Q3 2025
| Trial / Readout | Formulation / Dose | Key Endpoint Result |
|---|---|---|
| Phase 1 SAD/MAD (single/multi ascending dose) | Subcutaneous injectable | Early Phase 1 demonstrated dose-related weight reduction with a positive safety + tolerability profile, supporting Phase 2 advancement (2022) |
| Phase 2 VENTURE (obesity, 13 weeks) | Injectable; 2.5mg / 5mg / 10mg / 15mg weekly | Feb 27, 2024 topline: weight loss from baseline of 9.1% (2.5mg), 10.9% (5mg), 12.9% (10mg), and 14.7% (15mg) vs 1.7% placebo at 13 weeks; 15mg placebo-adjusted 13.1 points; 176 participants (NCT06068946). The readout re-rated VKTX sharply higher |
| Phase 1 oral VK2735 (28 days) | Oral tablet; up to 40mg | Mar 26, 2024 readout: up to 5.3% weight loss from baseline (3.3 points placebo-adjusted) at 28 days in the 40mg cohort; supported advancing the oral tablet to Phase 2 |
| Phase 2 VENTURE-Oral (obesity, 13 weeks) | Oral tablet; multiple doses | Aug 19, 2025 topline: up to 12.2% (26.6 lbs) mean weight loss at 13 weeks vs 1.3% placebo; 280 participants; up to 97% achieved >=5% and up to 80% achieved >=10% weight loss |
| Phase 3 VANQUISH-1 (obesity, registrational) | Injectable; pivotal, 78-week | Phase 3 subcutaneous VK2735 once-weekly for 78 weeks; ~4,650 adults with obesity or overweight with a comorbidity; enrollment completed November 2025 |
| Phase 3 VANQUISH-2 (T2D + obesity, registrational) | Injectable; pivotal, 78-week | Phase 3 subcutaneous VK2735 once-weekly for 78 weeks; ~1,000 adults with type 2 diabetes and obesity or overweight; enrollment completed March 2026 |
| Oral VK2735 Phase 3 (planned) | Oral tablet; pivotal | Viking has guided advancing oral VK2735 into a Phase 3 obesity program (targeted 3Q 2026 per company guidance) |
| Competitive comparison: tirzepatide vs semaglutide vs VK2735 | Phase 2 weight loss benchmark | VK2735 high-dose 14.7% from baseline at 13 weeks (injectable); tirzepatide ~22% at 72 weeks (SURMOUNT-1, Phase 3); semaglutide ~15% at 68 weeks (STEP 1, Phase 3). Cross-trial comparison is limited: VK2735's 13-week timepoint is much shorter, leaving longer-duration efficacy to be established in Phase 3 |
| Acquisition rumor history | Repeated speculation 2024-2025 | VKTX has been a rumored acquisition target for LLY + Pfizer + Roche at various points 2024-2025; management has stated it is open to partnerships but prefers a standalone path; market-cap volatility reflects acquisition speculation cycles |
| Editorial. Why VKTX matters | Strategic context | VKTX is the most credible standalone biotech challenger to the LLY/NVO duopoly. Its injectable + oral parallel development could compete in both segments at a price point below brand drugs. The marquee equity question: standalone commercial launch (high risk + high reward) vs acquisition (de-risked + immediate value monetization) |
2015-2025
$VKTX
Lead asset VK2735: dual GLP-1/GIP in oral and injectable formulations. VENTURE-Oral Phase 2 hit 10.9% placebo-adjusted weight loss at 13 weeks. Most-discussed mid-cap obesity pure-play; repeated M&A speculation.